Caristo Diagnostics has announced that the US Food and Drug Administration (FDA) has granted de novo authorisation for its CaRi-Heart technology for the quantification of coronary inflammation from routine coronary CT angiography (CCTA). CaRi-Heart unmasks previously hidden inflammation and provides clinicians with actionable insights, enabling earlier intervention and personalised treatments for patients, the company says […] The post AI-powered coronary inflammation quantification tool given US FDA de novo authorisation appeared first on Cardiovascular News .